Johnson & Johnson: Headline Risk But Business Solid

8/8/18

Summary

We remain big fans of the steady hand displayed by the venerable Johnson & Johnson as the pharmaceutical bellwether continues to perform admirably.

During its second-quarter results, we came away impressed with the continued strength in the Oncology division, which masks the deceleration in growth in Cardiovascular Disease.

There continues to be headline risk with respect to talcum powder litigation, but J&J's underlying business remains solid, in our view.

By Alexander J. Poulos

Examining J&J's Franchise Strength

We think a close examination of the underlying trends of Johnson & Johnson's (JNJ) three largest components of its pharma division will be helpful to readers. The company remains a stalwart in the high-growth branded pharmaceutical sector, an area that will continue to have an outsize impact on J&J's overall growth. Though most of the recent news headlines have focused on litigation risk with respect to talcum powder lawsuits, we think this risk is manageable for J&J, even if it may sting a bit. J&J remains one of our favorite ideas, but we'd be much happier if it could put its litigation risk behind it, of course.

READ FULL ARTICLE HERE